← Back to Treatments
🏅 FDA Orphan Designation

Gocovri

Amantadine hydrochloride

Manufacturer: Adamas Pharmaceuticals, Inc.

Indicated for:
Paroxysmal exertion-induced dyskinesiaOrphanYoung-onset Parkinson diseasePeroxisomal disease with epilepsy

FDA-Approved Indications (3)

treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy with or without concomitant dopminergic medications

For the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications

Population: patients with Parkinson's disease receiving levodopa-based therapy

As adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes

Population: patients with Parkinson's disease experiencing "off" episodes

Indications & Usage

1 INDICATIONS AND USAGE GOCOVRI ® is indicated: For the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications As adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes GOCOVRI ® is indicated: For the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications ( 1 ) As adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes ( 1 )

💙 Support Programs

View all →
Gocovri
Adamas Pharmaceuticals, Inc.

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.